Exagen stock price target raised to $10 from $7 at Cantor Fitzgerald

Published 30/07/2025, 12:54
Exagen stock price target raised to $10 from $7 at Cantor Fitzgerald

Investing.com - Cantor Fitzgerald raised its price target on Exagen (NASDAQ:XGN), a company with a market capitalization of $186 million, to $10.00 from $7.00 on Wednesday, while maintaining an Overweight rating on the stock. According to InvestingPro, the stock is currently trading near its 52-week high of $8.80.

The price target increase follows Exagen’s strong second-quarter 2025 operating results, which showed revenue of $17.2 million, exceeding both Cantor Fitzgerald’s estimate of $16.4 million and the FactSet consensus of $16.3 million. This represents year-over-year growth of 11%, with the company maintaining a healthy gross profit margin of 59.3%.

The company’s performance was driven by its AVISE CTD product, which achieved a trailing 12-month average selling price of $428, up approximately 7% year-over-year. Exagen also grew AVISE CTD test volume by approximately 14% quarter-over-quarter and 7% year-over-year.

Exagen has updated its fiscal year 2025 revenue guidance to a range of $65 million to $70 million, compared to its previous guidance of at least $65 million. The new guidance represents year-over-year growth of approximately 17% to 26%.

Exagen shares traded up approximately 14.3% on Tuesday, compared to the S&P 500 which was down about 0.9% at market close.

In other recent news, Exagen Inc . reported its second-quarter 2025 earnings, with revenue reaching $17.2 million, surpassing expectations and marking the highest quarterly revenue in the company’s history. However, the company’s earnings per share (EPS) reported a loss of $0.21, falling short of the anticipated $0.15 loss. This mixed financial performance did not deter investor enthusiasm, as the revenue growth and future outlook were positively received. Additionally, KeyBanc upgraded Exagen’s stock rating from Sector Weight to Overweight, establishing a price target of $12.00. The upgrade was attributed to improved visibility on revenue growth, with KeyBanc noting that Exagen’s revenue guidance suggests growth of 17-25% in 2025. These recent developments highlight a period of significant activity for Exagen, drawing attention from investors and analysts alike.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.